IMA203 not checked

Immatics US, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
4 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy”In the company’s words, NCT06743126 on ClinicalTrials.gov
Tested for
Melanoma, Cutaneous Malignant, Mucosal Melanoma, Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer, Cutaneous Melanoma, Synovial Sarcoma
Main trialPhase 3
“This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma or mucosal melanoma (MM). For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/”In the company’s words, NCT06743126 on ClinicalTrials.gov
Other names
anzutresgene autoleucel · anzu-cel

Other drugs for Mucosal Melanoma

All 195 drugs for Mucosal Melanoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jan 2028 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Phase 1/2Recruiting Dec 2028 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1Recruiting Aug 2029 ACTengine® IMA203 Combined With mRNA-4203
Phase 1/2Authorised not given A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IMA203

Following is part of Solo: you see every change to IMA203 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in